Introduction {#section5-1758835919838960}
============

Multimodality treatment has been the basic tenet in the treatment of advanced colorectal cancer (CRC) with the aim of improving prognoses.^[@bibr1-1758835919838960]^ In addition to complete surgical resection, adjuvant chemotherapy (AC) in resected CRC has been attracting increasing interest. Previous clinical trials showed that 5-fluorouracil (5-FU) based AC was effective for reducing recurrence and thereby contributed to longer overall survival (OS) in patients with stage III CRC.^[@bibr2-1758835919838960][@bibr3-1758835919838960][@bibr4-1758835919838960][@bibr5-1758835919838960]--[@bibr6-1758835919838960]^ Moreover, oxaliplatin-including AC further improved the long-term prognosis of stage III colon patients.^[@bibr7-1758835919838960][@bibr8-1758835919838960]--[@bibr9-1758835919838960]^ However, the efficacy of AC after curative resection for stage IV CRC has been debated, with conflicting reports of benefits. Several randomized trials on 5-FU-based AC failed to demonstrate any survival benefit in CRC patients who underwent the resection of liver metastases after curative resection.^[@bibr10-1758835919838960][@bibr11-1758835919838960]--[@bibr12-1758835919838960]^ On the other hand, a recent phase III randomized controlled trial (RCT) showed that oral tegafur/uracil and leucovorin significantly prolonged recurrence-free survival (RFS) in CRC patients with synchronous or metachronous liver-limited metastases after primary resection and hepatectomy.^[@bibr13-1758835919838960]^ However, the trial did not prove an OS benefit by oral AC in this patient cohort.^[@bibr13-1758835919838960]^ Moreover, the efficacy of AC after curative resection for CRC with synchronous metastases in various organs remains unclear because of the paucity of systematic studies.

In stage II CRC, AC has only been recommended for selected patients with high-risk features, such as pathological T4, poorly differentiated histology, suboptimal lymph node retrieval, bowel perforation, bowel obstruction, lymphatic and venous invasion, perineural invasion, and positive resection margins.^[@bibr14-1758835919838960][@bibr15-1758835919838960][@bibr16-1758835919838960]--[@bibr17-1758835919838960]^ Subgroup analyses of controlled trials on stage II and III CRC have generally indicated that survival rates were increased by AC in patients with stage III disease, but not in those with stage II.^[@bibr3-1758835919838960],[@bibr7-1758835919838960],[@bibr18-1758835919838960],[@bibr19-1758835919838960]^ These findings suggest that the benefit of adjuvant therapy partly depends on the nodal status,^[@bibr19-1758835919838960]^ although DNA microsatellite instability (MSI) status was also reported to predict the efficacy of 5-FU-based AC.^[@bibr20-1758835919838960],[@bibr21-1758835919838960]^ Furthermore, retrospective cohort studies recently demonstrated that the presence of regional lymph node metastases had a negative impact on survival in patients with resectable and/or unresectable stage IV CRC.^[@bibr22-1758835919838960][@bibr23-1758835919838960]--[@bibr24-1758835919838960]^ The different efficacy of AC between stage II and stage III CRC motivated us to investigate whether the effectiveness of AC depends on regional spread of cancer or any cancer spread beyond the primary tumor in stage IV CRC.

Toward this end, the present study investigated the clinical significance of AC in CRC patients with various organ metastases after curative resection using a propensity score method. The associations between the effectiveness of AC and clinicopathological factors including regional nodal involvement were also analyzed.

Patients and methods {#section6-1758835919838960}
====================

This study was conducted with the approval of the ethics committee of the University of Tokyo Hospital (reference number: 3252-6). For inclusion in this study, written informed consent was obtained from each patient, and the opportunity to opt out was also offered.

Patients and clinicopathological parameters {#section7-1758835919838960}
-------------------------------------------

We retrospectively reviewed consecutive CRC patients diagnosed with synchronous distant organ metastases who underwent curative surgery in the University of Tokyo Hospital between January 2003 and December 2017. Patients who underwent chemotherapy and/or radiotherapy before radical surgery and those with multiple primary CRCs were excluded from the present study. Demographic data, such as the period of surgery, gender, age, the European Cooperative Oncology Group Performance Status (PS), and serum levels of hemoglobin, albumin, and the tumor markers carcinoembryonic antigen (CEA) and carbohydrate antigen (CA) 19-9 at diagnosis and immediately before surgery were retrospectively retrieved from medical records. In our institute, the lower normal limit of serum hemoglobin is 13.7 g/dl (men) or 11.6 g/dl (women), and that of serum albumin is 4.1 g/dl, whereas the upper normal limits of serum CEA and CA 19-9 are 5.0 ng/ml and 37 U/ml, respectively. Information was obtained on the primary tumor, including location, size, obstruction, histology, tumor depth, regional lymph node metastasis, lymphatic and venous invasion, the *KRAS* exon 2 status, and MSI status judged based on two mononucleotide repeat markers, *BAT25* and *BAT26*,^[@bibr25-1758835919838960]^ if available; all resected specimens were histologically examined and documented according to the guidelines established by the eighth edition of the American Joint Committee on Cancer staging system^[@bibr26-1758835919838960]^ and the guidelines of the Japanese Society for Cancer of the Colon and Rectum (JSCCR).^[@bibr27-1758835919838960]^ Metastasized organs, intraoperative blood transfusions, and postoperative complications graded by the Clavien--Dindo classification^[@bibr28-1758835919838960]^ were also reviewed.

Adjuvant chemotherapy and follow-up {#section8-1758835919838960}
-----------------------------------

Typical AC included oral 5-FU (+ folinate) and oral/infusional 5-FU and oxaliplatin for 6 months. The duration was chosen in accordance with the National Comprehensive Cancer Network guidelines.^[@bibr15-1758835919838960],[@bibr16-1758835919838960]^ mFOLFOX6 (oxaliplatin 85 mg/m^2^ and folinate 200 mg/m^2^, followed by 5-FU as a 400 mg/m^2^ intravenous bolus and 2400 mg/m^2^ infusion over 46 h) was administered every 2 weeks (total: 12 planned cycles).^[@bibr29-1758835919838960]^ CapeOX (oxaliplatin 130 mg/m^2^ over 2 hours on day 1 and oral capecitabine 1000 mg/m^2^ twice daily on days 1--14) was repeated every 3 weeks (total: eight planned cycles).^[@bibr9-1758835919838960]^ SOX (oxaliplatin 130 mg/m^2^ over 2 hours on day 1 and oral S-1 40 mg/m^2^ twice daily on days 1--14) was repeated every 3 weeks (total: eight planned cycles).^[@bibr30-1758835919838960]^ Some patients were recruited into RCTs; for example, a trial investigating tegafur/uracil after R0 resection for liver metastases from CRC conducted in our hospital between 2004 and 2010.^[@bibr13-1758835919838960]^ In other patients, the implementation of AC depended on the patient's preference and condition and/or the doctor's discretion. The severity of adverse events and laboratory findings were graded in accordance with the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0.^[@bibr31-1758835919838960]^

Patients were evaluated for tumor recurrence by a physical examination, serum tumor marker measurement, computed tomography scans every 6 months, and colonoscopy annually after curative surgery. When a new manifestation of symptoms occurred suggesting recurrent disease or serum tumor marker levels increased in a rapid manner, imaging studies including other modalities such as magnetic resonance imaging and positron emission tomography were additionally performed. RFS was defined as the time between the complete removal and diagnosis of any recurrence, and OS as the time between the first surgery and death from any cause. Data were collected up to the end of August 2018.

Statistical analysis {#section9-1758835919838960}
--------------------

Categorized data in each group were compared by the Chi-squared or Fisher's exact probability test, whereas continuous variables were compared by Student's *t* test or Wilcoxon rank-sum test. Prognostic factors were estimated by univariate and multivariate analyses using Cox's proportional hazard model, in which several variables were dichotomized by the mean value or normal limit (age, hemoglobin and albumin levels, tumor size, pT, and pN) or trichotomized (tumor location). The inverse probability of the treatment weighting (IPTW) method^[@bibr32-1758835919838960],[@bibr33-1758835919838960]^ was used to reduce the selection bias between the two treatment groups. Covariates in the models for propensity scores included all clinicopathological factors, except for the *KRAS* exon 2 and MSI status because there were patients without the results of these genetic tests. In order to estimate RFS and OS, the adjusted Kaplan--Meier method with the log-rank test was performed by weighting each patient receiving AC by the inverse of the propensity score and each patient without AC by the inverse of (1 -- the propensity score). The statistical analysis of data was performed using JMP Pro 14.0.0 software (SAS Institute Inc., Cary, NC, USA), and *p* values **\<** 0.05 were considered to be significant.

Results {#section10-1758835919838960}
=======

Patients and adjuvant chemotherapy {#section11-1758835919838960}
----------------------------------

Among 155 patients (94 males and 61 females, mean age: 62.8 years old) with stage IV CRC during the study period, 103 (66%) received AC; 51 received 5-FU (and folinate), 30 mFOLFOX6, 15 CapeOX, and 7 SOX. When all patients were divided into two groups according to the period of surgery (2003--2010 and 2011--2017), the first period accounted for 63% of patients who did not receive AC whereas the second period accounted for 57% of patients treated with AC (*p* = 0.015). Fifteen patients were participants in previous RCTs, 11 of whom were administered AC (two tegafur/uracil plus folinate, two FOLFOX, and seven SOX). [Table 1](#table1-1758835919838960){ref-type="table"} summarizes the characteristics of stage IV CRC patients stratified by AC. Regional lymph node metastases were detected more frequently in patients treated with AC than in those not treated with AC (83% *versus* 69%, *p* = 0.041). Patients treated with AC were also characterized by a more frequent PS of 0 (98% *versus* 85%, *p* = 0.003), higher level of albumin (mean: 3.8 g/dl *versus* 3.6 g/dl, *p* = 0.011), more frequent peritoneal metastasis (27% *versus* 10%, *p* = 0.012), and less frequent blood transfusions (15% *versus* 35%, *p* = 0.004). No significant differences were observed in other parameters between these two groups. The characteristics of stage IV CRC patients who received AC were similar between 5-FU-based and oxaliplatin-including regimens, except for the period of surgery ([Supplemental Table 1](https://journals.sagepub.com/doi/suppl/10.1177/1758835919838960)); 73% of patients who underwent surgery in 2003--2010 were treated by 5-FU-based AC, whereas 87% of those in 2011--2017 were treated by oxaliplatin-based AC (*p* \< 0.0001).

###### 

Baseline characteristics of patients with stage IV colorectal cancer according to adjuvant chemotherapy.

![](10.1177_1758835919838960-table1)

  Variables                                                                                                                                                        No AC         AC            *p* value
  ---------------------------------------------------------------------------------------- ----------------------------------------------------------------------- ------------- ------------- -----------
  Period of surgery                                                                        2003--2010                                                              33 (63%)      44 (43%)      0.015
                                                                                           2011--2017                                                              19 (37%)      59 (57%)      
  Age, year                                                                                Mean ± SD                                                               64.5 ± 12.3   62.0 ± 10.7   0.18
  Gender                                                                                   Male                                                                    35 (67%)      59 (57%)      0.23
  ECOG PS                                                                                  0                                                                       44 (85%)      101 (98%)     0.003
                                                                                           1                                                                       8 (15%)       2 (2%)        
  Hemoglobin, g/dl                                                                         Mean ± SD                                                               11.7 ± 2.5    12.1 ± 1.8    0.29
  Albumin, g/dl                                                                            Mean ± SD                                                               3.6 ± 0.5     3.8 ± 0.4     0.011
  CEA                                                                                      Elevated                                                                37 (71%)      79 (77%)      0.45
  CA 19-9                                                                                  Elevated                                                                (44%)         50 (49%)      0.61
  Primary site                                                                             Right-sided colon                                                       11 (21%)      27 (26%)      0.19
                                                                                           Left-sided colon                                                        15 (29%)      40 (39%)      
                                                                                           Rectum                                                                  26 (50%)      36 (35%)      
  Size of primary cancer, mm ^[a](#table-fn2-1758835919838960){ref-type="table-fn"}^       Mean ± SD                                                               58.0 ± 21.2   52.2 ± 20.7   0.11
  Obstruction                                                                              Yes                                                                     24 (46%)      52 (50%)      0.61
  Histology                                                                                Differentiated^[b](#table-fn2-1758835919838960){ref-type="table-fn"}^   48 (92%)      91 (88%)      0.63
                                                                                           Others                                                                  4 (8%)        12 (12%)      
  Depth                                                                                    -pT3                                                                    26 (50%)      39 (38%)      0.15
                                                                                           pT4                                                                     26 (50%)      64 (62%)      
  Regional lymph node metastasis                                                           Yes                                                                     36 (69%)      86 (83%)      0.041
  Lymphatic invasion                                                                       Yes                                                                     23 (44%)      62 (60%)      0.059
  Venous invasion                                                                          Yes                                                                     46 (88%)      93 (90%)      0.94
  *KRAS* exon 2 status^[c](#table-fn2-1758835919838960){ref-type="table-fn"}^              Wild-type                                                               13 (76%)      26 (54%)      0.19
                                                                                           Mutant                                                                  4 (24%)       22 (46%)      
  DNA microsatellite instability ^[c](#table-fn2-1758835919838960){ref-type="table-fn"}^   Stable                                                                  33 (100%)     79 (100%)     1.00
  Number of metastasized organs                                                            1                                                                       50 (96%)      90 (87%)      0.092
                                                                                           2                                                                       2 (4%)        13 (13%)      
  Metastasized organs                                                                      Liver                                                                   42 (81%)      72 (70%)      0.15
                                                                                           Lung                                                                    3 (6%)        8 (8%)        0.75
                                                                                           Distant lymph nodes                                                     3 (6%)        4 (4%)        0.69
                                                                                           Peritoneum                                                              5 (10%)       28 (27%)      0.012
                                                                                           Ovary                                                                   1 (2%)        2 (2%)        1.00
                                                                                           Others                                                                  0 (0%)        2 (2%)        0.55
  Blood transfusions                                                                       Yes                                                                     18 (35%)      15 (15%)      0.004
  Postoperative complications                                                              Grade 2-                                                                24 (46%)      36 (35%)      0.18

AC, adjuvant chemotherapy; CA 19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen; ECOG, Eastern Cooperative Oncology Group; PS, performance status; SD, standard deviation.

excluding one unavailable case; ^b^ differentiated adenocarcinoma; ^c^ excluding cases that were not evaluated.

The mean period of AC was 6.7 months. Adverse events were assessable in 101 out of the 103 patients who underwent AC. Neutropenia was the most common as a grade 3 or grade 4 event (16 patients, 16%), followed by neuropathy (three patients, 3%), infection (two patients, 2%), and diarrhea (two patients, 2%). No AC-related deaths occurred.

Prognostic factors in stage IV CRC {#section12-1758835919838960}
----------------------------------

The median follow-up time was 54.3 months. Postoperative recurrence was observed in 43 (83%) of the 52 patients without AC and 71 (69%) of the 103 patients who received AC. Twenty-five patients without AC and 34 with AC died during the follow-up period. In order to confirm whether AC is a significant prognostic factor in stage IV CRC, we conducted univariate and multivariate analyses on RFS and OS. As shown in [Table 2](#table2-1758835919838960){ref-type="table"}, surgery in 2003--2010, lymphatic invasion, and no AC were independent parameters associated with worse RFS. [Table 3](#table3-1758835919838960){ref-type="table"} shows the results of univariate and multivariate analyses for OS. Elevated CA 19-9, histology other than differentiated adenocarcinoma, lymphatic invasion, and no AC were independent factors for predicting worse OS.

###### 

Analyses of predictive factors for recurrence-free survival.

![](10.1177_1758835919838960-table2)

  Variables                                                                                            Univariate   Multivariate        
  ---------------------------------------------------------------------------------------------------- ------------ ------------------- -------
  Period of surgery                                                                                    0.0006       1.52 (1.01--2.29)   0.044
  Age (\< 63 *versus* ⩾ 63 years old)                                                                  0.042        1.42 (0.97--2.10)   0.073
  Sex (male *versus* female)                                                                           0.16                             
  ECOG PS (1 *versus* 0)                                                                               0.45                             
  Hemoglobin (high *versus* normal)                                                                    0.50                             
  Albumin (high *versus* normal)                                                                       0.60                             
  CEA (high *versus* normal)                                                                           0.62                             
  CA 19-9 (high *versus* normal)                                                                       0.24                             
  Primary site (rectum *versus* left-sided colon/right-sided colon)                                    0.059                            
  Size of primary cancer (\< 55 *versus* ⩾ 55 mm)                                                      0.26                             
  Obstruction (yes *versus* no)                                                                        0.79                             
  Histology (differentiated ^[a](#table-fn4-1758835919838960){ref-type="table-fn"}^ *versus* others)   0.10                             
  Depth (pT4 *versus* pT3)                                                                             0.12                             
  Lymphatic invasion (yes *versus* no)                                                                 0.031        1.54 (1.05--2.26)   0.026
  Venous invasion (yes *versus* no)                                                                    0.94                             
  *KRAS* exon 2 status (mutant *versus* wild-type)                                                     0.61                             
  Liver metastases (yes *versus* no)                                                                   0.36                             
  Lung metastases (yes *versus* no)                                                                    0.076                            
  Distant lymph node metastases (yes *versus* no)                                                      0.92                             
  Peritoneal metastases (yes *versus* no)                                                              0.14                             
  Ovarian metastases (yes *versus* no)                                                                 0.87                             
  Blood transfusions (yes *versus* no)                                                                 0.032        1.45 (0.92--2.24)   0.11
  Postoperative complications (grade 2 *versus* grade 0/1)                                             0.096                            
  Adjuvant chemotherapy (no *versus* yes)                                                              0.0007       1.86 (1.24--2.77)   0.003

CA 19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; PS, performance status.

differentiated adenocarcinoma.

###### 

Analyses of predictive factors for overall survival.

![](10.1177_1758835919838960-table3)

  Variables                                                                                            Univariate   Multivariate        
  ---------------------------------------------------------------------------------------------------- ------------ ------------------- -------
  Period of surgery                                                                                    0.18                             
  Age (\< 63 *versus* ⩾ 63 years old)                                                                  0.83                             
  Sex (male *versus* female)                                                                           0.70                             
  ECOG PS (1 *versus* 0)                                                                               0.020        2.55 (0.86--6.42)   0.087
  Hemoglobin (high *versus* normal)                                                                    0.67                             
  Albumin (high *versus* normal)                                                                       0.82                             
  CEA (high *versus* normal)                                                                           0.87                             
  CA 19-9 (high *versus* normal)                                                                       0.037        2.29 (1.34--3.96)   0.003
  Primary site (rectum *versus* left-sided colon/right-sided colon)                                    0.31                             
  Size of primary cancer (\< 55 *versus* ⩾ 55 mm)                                                      0.52                             
  Obstruction (yes *versus* no)                                                                        0.090                            
  Histology (differentiated ^[a](#table-fn6-1758835919838960){ref-type="table-fn"}^ *versus* others)   0.002        0.40 (0.19--0.87)   0.023
  Depth (pT4 *versus* pT3)                                                                             0.080                            
  Lymphatic invasion (yes *versus* no)                                                                 0.033        1.83 (1.03--3.33)   0.039
  Venous invasion (yes *versus* no)                                                                    0.78                             
  *KRAS* exon 2 status (mutant *versus* wild-type)                                                     0.15                             
  Liver metastases (yes *versus* no)                                                                   0.002        0.82 (0.34--2.11)   0.67
  Lung metastases (yes *versus* no)                                                                    0.37                             
  Distant lymph node metastases (yes *versus* no)                                                      0.17                             
  Peritoneal metastases (yes *versus* no)                                                              0.007        2.15 (0.87--5.55)   0.10
  Ovarian metastases (yes *versus* no)                                                                 0.47                             
  Blood transfusions (yes *versus* no)                                                                 0.29                             
  Postoperative complications (grade 2 *versus* grade 0/1)                                             0.024        1.61 (0.95--2.76)   0.079
  Adjuvant chemotherapy (no *versus* yes)                                                              0.007        2.66 (1.44--4.92)   0.002

CA 19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; PS, performance status.

Differentiated adenocarcinoma.

RFS and OS in propensity-matched cohorts {#section13-1758835919838960}
----------------------------------------

In order to mitigate clinicopathological backgrounds between patients receiving AC and those who did not, we performed propensity score matching using the IPTW method. We analyzed RFS according to AC in the adjusted cohorts of stage IV CRC patients. The 2-year and 5-year RFS rates were 28% and 25% for patients receiving AC, which were higher than those for patients without AC (19% and 16%, *p* \< 0.0001, [Figure 1](#fig1-1758835919838960){ref-type="fig"}). Similarly, OS curves were compared between patients receiving AC and those without AC in the same adjusted cohorts. The 2-year and 5-year OS rates were 88% and 66% for patients receiving AC, which were higher than those for patients without AC (76% and 46%, *p* = 0.0008, [Figure 2](#fig2-1758835919838960){ref-type="fig"}).

![Adjusted recurrence-free survival curves in stage IV colorectal cancer patients according to adjuvant chemotherapy (AC) using the inverse probability of treatment weighted method. The bold line indicates the survival curve of patients receiving AC, and the dashed line that of those who did not receive AC.](10.1177_1758835919838960-fig1){#fig1-1758835919838960}

![Adjusted overall survival curves in stage IV colorectal cancer patients according to adjuvant chemotherapy (AC) using the inverse probability of treatment weighted method. The bold line indicates the survival curve of patients receiving AC, and the dashed line that of those who did not receive AC.](10.1177_1758835919838960-fig2){#fig2-1758835919838960}

Subgroup analyses for RFS and OS {#section14-1758835919838960}
--------------------------------

We performed subgroup analyses to further explore the advantages of AC in the adjusted cohorts stratified by clinicopathological factors. [Figure 3](#fig3-1758835919838960){ref-type="fig"} shows the results of subgroup analyses for RFS. Generally, the effect of AC on reducing the risk of recurrence was consistent across subgroups, with the exception of hemoglobin level, primary tumor location, histology, venous invasion, lung and distant lymph node metastases, and intraoperative blood transfusions. AC improved RFS in both patients with regional lymph node metastases (pN+ ) and those without nodal involvement (pN0) \[hazard ratio: 2.16, 95% confidence interval (CI): 1.08--4.36, *p* = 0.029, and hazard ratio: 2.03, 95% CI: 1.50--2.75, *p* \< 0.0001, respectively\].

![Adjusted hazard ratio for recurrence-free survival with adjuvant chemotherapy (AC) *versus* no AC according to subgroups defined on the basis of baseline factors and perioperative variables.\
CI, confidence interval.](10.1177_1758835919838960-fig3){#fig3-1758835919838960}

In contrast, subgroups that showed a reduced risk of death were limited, as shown in [Figure 4](#fig4-1758835919838960){ref-type="fig"}. AC markedly improved OS in patients with pN+ (hazard ratio: 2.02, 95% CI: 1.33--3.06, *p* = 0.001), whereas the effect of AC on OS was not significant in pN0 patients (hazard ratio: 2.02, 95% CI: 0.53--6.00, *p* = 0.36). However, the *p* value for interaction between AC and regional nodal metastases was 0.78.

![Adjusted hazard ratio for overall survival with adjuvant chemotherapy (AC) *versus* no AC according to subgroups defined on the basis of baseline factors and perioperative variables.\
CI, confidence interval.](10.1177_1758835919838960-fig4){#fig4-1758835919838960}

Discussion {#section15-1758835919838960}
==========

Optimal treatments for patients with resectable stage IV CRC remain controversial. Standard treatments include complete resection of the primary tumor and all metastases when they were limited.^[@bibr15-1758835919838960],[@bibr16-1758835919838960]^ In resectable stage IV CRC without any preoperative therapy, retrospective studies previously showed the positive impact of AC on postoperative survival.^[@bibr22-1758835919838960],[@bibr34-1758835919838960],[@bibr35-1758835919838960]^ In addition, an RCT showed a significant increase in RFS by oral 5-FU and folinate, whereas OS was not affected by this AC regimen after the resection of synchronous or metachronous liver-limited metastases from CRC.^[@bibr13-1758835919838960]^ Since the percentage of pN+ patients who received AC was significantly smaller than those who did not in that study (*p* = 0.041),^[@bibr13-1758835919838960]^ the imbalance observed in the regional nodal status appears to have accounted for the improved RFS for the AC group. Therefore, we used the IPTW method in order to mitigate differences in pN and other clinicopathological factors that potentially affect long-term outcomes; we demonstrated that AC significantly prolonged RFS and OS in stage IV CRC patients. Moreover, the subgroup analyses showed that AC improved RFS in both pN0 and pN+ patients and OS in pN+ patients. Hence, the benefit of AC in stage IV CRC appeared independent of regional nodal involvement.

Difficulties are associated with conducting prospective studies on AC for stage IV CRC with extrahepatic distant metastases because it is less common than hepatic metastases. Alternatively, retrospective studies shared the majority of publications regarding this issue. The clinical significance of AC after pulmonary metastasectomy in CRC remains controversial. A French multi-institutional study showed slightly reduced rates of recurrence in patients with AC,^[@bibr36-1758835919838960]^ and a pooled analysis of published data did not reveal any change in OS by AC for resected lung metastases from CRC.^[@bibr37-1758835919838960]^ On the other hand, a single-center Korean study reported significant increases in OS by AC in CRC patients with resectable lung metastases; however, more than half of these patients had also received preoperative chemotherapy.^[@bibr38-1758835919838960]^ Furthermore, similar to the EPOC trial in CRC with resectable liver metastases,^[@bibr39-1758835919838960]^ several groups attempted perioperative chemotherapy for patients with resectable lung metastases from CRC.^[@bibr40-1758835919838960],[@bibr41-1758835919838960]^ Regarding peritoneal metastases, a multi-institutional database analysis of the JSCCR showed that AC was a significant factor for prolonged OS after the complete removal of peritoneal dissemination.^[@bibr23-1758835919838960]^ The effects of AC after the removal of primary CRC with synchronous involvement in distant lymph nodes, such as those of the para-aortic region, have not yet been examined.

In the present study, elevated CA 19-9, undifferentiated histology, and lymphatic invasion were other independent prognostic factors in resectable stage IV CRC. Several groups, including ours, reported elevated CA 19-9 as a prognostic marker in resectable stage IV CRC.^[@bibr23-1758835919838960],[@bibr42-1758835919838960]^ Shibutani and colleagues reported that tumor differentiation and lymphatic invasion together with preoperative serum C-reactive protein level were biomarkers for identifying patients with a poor cancer-specific survival for resectable and nonresectable stage IV CRC,^[@bibr43-1758835919838960]^ whereas our group previously reported lymphatic invasion as an independent factor for reduced RFS in stage IV CRC after R0 resection by a multivariate analysis.^[@bibr42-1758835919838960]^

Several pivotal studies demonstrated the benefits of oxaliplatin-based AC in addition to 5-FU for stage III CRC.^[@bibr6-1758835919838960][@bibr7-1758835919838960]--[@bibr8-1758835919838960]^ More than 50% of stage IV CRC cases relapse even after curative resection;^[@bibr1-1758835919838960]^ therefore, more intensive AC may be required to reduce recurrence. It remains unclear whether intensive regimens such as oxaliplatin-including therapy are more beneficial than 5-FU-based regimens for stage IV CRC. The aforementioned retrospective JSCCR study on R0 resection cases of peritoneal metastases showed that prognoses were better in patients receiving oxaliplatin-including AC.^[@bibr23-1758835919838960]^ Nakayama and colleagues reported that oxaliplatin-based chemotherapy was a feasible AC option for stage IV CRC regardless of hepatic and extrahepatic metastases.^[@bibr44-1758835919838960]^ mFOLFOX6 and SOX are currently being prospectively tested as AC regimens in stage IV CRC after curative hepatic resection.^[@bibr45-1758835919838960],[@bibr46-1758835919838960]^

There were several limitations in the present study due to its retrospective nature. The distribution and number of metastatic lesions varied among patients. AC included several different regimens and durations. The choice of AC and its regimen depended on patients' preferences and conditions and doctors' discretion for most patients. In addition, newer patients were more likely to receive AC, which may affect the survival outcomes. Moreover, we could not address the impact of MSI status because there were no MSI-positive cases in our cohort; there might be false-negative MSI cases, although Jass and colleagues mentioned that MSI tumors can be most efficiently screened by the combination of *BAT25* and *BAT26*.^[@bibr25-1758835919838960]^ In addition, there was no available data on MSI in patients who underwent surgery in the early days.

In conclusion, we herein demonstrated that AC had markedly positive impacts on RFS and OS in patients with curatively resected stage IV CRC. Taking into account the limitations of our study just mentioned, AC can be discussed with all resectable stage IV CRC patients. Our results need to be confirmed by further investigation, such as an independent validation study using another set of stage IV CRC patients. It is also very important to find reliable biomarkers associated with the efficacy of AC in resectable stage IV CRC.
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